ciprofloxacin

Summary

Summary: A broad-spectrum antimicrobial carboxyfluoroquinoline.

Top Publications

  1. pmc Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia coli
    Tobias Dörr
    Department of Biology, Northeastern University, Antimicrobial Discovery Center, Boston, Massachusetts, United States of America
    PLoS Biol 8:e1000317. 2010
  2. pmc Prevalence in the United States of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme
    Chi Hye Park
    Division of Infectious Diseases, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 2696, USA
    Antimicrob Agents Chemother 50:3953-5. 2006
  3. pmc Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin
    Marshall C Walters
    Center for Biofilm Engineering, Department of Chemical Engineering, Montana State University Bozeman, Bozeman, Montana 59717 3980, USA
    Antimicrob Agents Chemother 47:317-23. 2003
  4. ncbi Type IIA topoisomerase inhibition by a new class of antibacterial agents
    Benjamin D Bax
    Molecular Discovery Research, GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK
    Nature 466:935-40. 2010
  5. ncbi Structural changes induced by a lytic bacteriophage make ciprofloxacin effective against older biofilm of Klebsiella pneumoniae
    Vivek Verma
    Department of Microbiology, Basic Medical Sciences BMS Block, Panjab University, Chandigarh, India
    Biofouling 26:729-37. 2010
  6. ncbi Mechanisms of resistance to quinolones
    George A Jacoby
    Lahey Clinic, Burlington, Massachusetts 01805, USA
    Clin Infect Dis 41:S120-6. 2005
  7. ncbi Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase
    Ari Robicsek
    Harvard Medical School, Division of Infectious Diseases, Massachusetts General Hospital, 55 Fruit St, GRJ 512, Boston, Massachusetts 02114, USA
    Nat Med 12:83-8. 2006
  8. ncbi Enteric fever in Cambodian children is dominated by multidrug-resistant H58 Salmonella enterica serovar Typhi with intermediate susceptibility to ciprofloxacin
    Kate Emary
    Mahidol Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand
    Trans R Soc Trop Med Hyg 106:718-24. 2012
  9. pmc Complete and SOS-mediated response of Staphylococcus aureus to the antibiotic ciprofloxacin
    Ryan T Cirz
    Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA
    J Bacteriol 189:531-9. 2007
  10. pmc Role of nutrient limitation and stationary-phase existence in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin
    Jeff N Anderl
    Center for Biofilm Engineering, Montana State University, Bozeman, Montana 59717 3980, USA
    Antimicrob Agents Chemother 47:1251-6. 2003

Detail Information

Publications369 found, 100 shown here

  1. pmc Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia coli
    Tobias Dörr
    Department of Biology, Northeastern University, Antimicrobial Discovery Center, Boston, Massachusetts, United States of America
    PLoS Biol 8:e1000317. 2010
    ..a knockout of a particular SOS-TA locus, tisAB/istR, had a sharply decreased level of persisters tolerant to ciprofloxacin, an antibiotic that causes DNA damage...
  2. pmc Prevalence in the United States of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme
    Chi Hye Park
    Division of Infectious Diseases, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 2696, USA
    Antimicrob Agents Chemother 50:3953-5. 2006
    Among 313 Enterobacteriaceae from the United States with a ciprofloxacin MIC of >/=0.25 microg/ml and reduced susceptibility to ceftazidime, aac(6')-Ib was present in 50...
  3. pmc Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin
    Marshall C Walters
    Center for Biofilm Engineering, Department of Chemical Engineering, Montana State University Bozeman, Bozeman, Montana 59717 3980, USA
    Antimicrob Agents Chemother 47:317-23. 2003
    ..Tobramycin and ciprofloxacin penetrated biofilms but failed to effectively kill the bacteria...
  4. ncbi Type IIA topoisomerase inhibition by a new class of antibacterial agents
    Benjamin D Bax
    Molecular Discovery Research, GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK
    Nature 466:935-40. 2010
    ..This work provides new insights into the mechanism of topoisomerase action and a platform for structure-based drug design of a new class of antibacterial agents against a clinically proven, but conformationally flexible, enzyme class...
  5. ncbi Structural changes induced by a lytic bacteriophage make ciprofloxacin effective against older biofilm of Klebsiella pneumoniae
    Vivek Verma
    Department of Microbiology, Basic Medical Sciences BMS Block, Panjab University, Chandigarh, India
    Biofouling 26:729-37. 2010
    ..It has been documented that young biofilm of Klebsiella pneumoniae could be eradicated significantly by ciprofloxacin treatment alone...
  6. ncbi Mechanisms of resistance to quinolones
    George A Jacoby
    Lahey Clinic, Burlington, Massachusetts 01805, USA
    Clin Infect Dis 41:S120-6. 2005
    ..Although Qnr by itself produces only low-level resistance, its presence facilitates the selection of higher-level resistance mutations, thus contributing to the alarming increase in resistance to quinolones...
  7. ncbi Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase
    Ari Robicsek
    Harvard Medical School, Division of Infectious Diseases, Massachusetts General Hospital, 55 Fruit St, GRJ 512, Boston, Massachusetts 02114, USA
    Nat Med 12:83-8. 2006
    ..We describe reduced susceptibility to ciprofloxacin in clinical bacterial isolates conferred by a variant of the gene encoding aminoglycoside acetyltransferase ..
  8. ncbi Enteric fever in Cambodian children is dominated by multidrug-resistant H58 Salmonella enterica serovar Typhi with intermediate susceptibility to ciprofloxacin
    Kate Emary
    Mahidol Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand
    Trans R Soc Trop Med Hyg 106:718-24. 2012
    ..resistant (MDR: resistant to chloramphenicol, ampicillin, trimethoprim-sulphamethoxazole) with intermediate ciprofloxacin susceptibility are widespread in Asia but there is little information from Cambodia...
  9. pmc Complete and SOS-mediated response of Staphylococcus aureus to the antibiotic ciprofloxacin
    Ryan T Cirz
    Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA
    J Bacteriol 189:531-9. 2007
    ..antibiotic therapy and eventually emerges resistant, we characterized its global transcriptional response to ciprofloxacin. We found that ciprofloxacin induces prophage mobilization as well as significant alterations in metabolism, ..
  10. pmc Role of nutrient limitation and stationary-phase existence in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin
    Jeff N Anderl
    Center for Biofilm Engineering, Montana State University, Bozeman, Montana 59717 3980, USA
    Antimicrob Agents Chemother 47:1251-6. 2003
    Biofilms formed by Klebsiella pneumoniae resisted killing during prolonged exposure to ampicillin or ciprofloxacin even though these agents have been shown to penetrate bacterial aggregates...
  11. ncbi Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group
    W Zimmerli
    Department of Internal Medicine, University Hospitals, Basel, Switzerland
    JAMA 279:1537-41. 1998
    ..Rifampin-containing regimens are able to cure staphylococcal implant-related infections based on in vitro and in vivo observations. However, this evidence has not been proven by a controlled clinical trial...
  12. pmc Pseudomonas aeruginosa increases formation of multidrug-tolerant persister cells in response to quorum-sensing signaling molecules
    Nina Möker
    Department of Infectious Diseases, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA
    J Bacteriol 192:1946-55. 2010
    ..aeruginosa PAO1 or PA14 cultures but not in E. coli or S. aureus cultures...
  13. pmc Inhibition of mutation and combating the evolution of antibiotic resistance
    Ryan T Cirz
    Department of Chemistry, The Scripps Research Institute, La Jolla, California, USA
    PLoS Biol 3:e176. 2005
    ..the activity of the protease LexA renders pathogenic Escherichia coli unable to evolve resistance in vivo to ciprofloxacin or rifampicin, important quinolone and rifamycin antibiotics...
  14. ncbi Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation
    Anskar Y H Leung
    Department of Medicine, University of Hong Kong, China
    Clin Infect Dis 40:528-37. 2005
    ..The objective of this study was to test whether standard-dose ciprofloxacin might suppress reactivation of BKV infection during HSCT.
  15. pmc Ciprofloxacin dosage and emergence of resistance in human commensal bacteria
    Bruno Fantin
    Universite Paris Diderot, Paris, France
    J Infect Dis 200:390-8. 2009
    ..Although optimization of the fluoroquinolone dosage increases the efficacy of this class of drugs against bacterial infections, its impact on the emergence of resistance in commensal bacteria is unknown...
  16. pmc Fitness costs and stability of a high-level ciprofloxacin resistance phenotype in Salmonella enterica serotype enteritidis: reduced infectivity associated with decreased expression of Salmonella pathogenicity island 1 genes
    Edel O'Regan
    Centre for Food Safety, UCD Veterinary Sciences Centre, University College Dublin, Belfield, Dublin 4, Ireland
    Antimicrob Agents Chemother 54:367-74. 2010
    ..with high-level fluoroquinolone resistance were examined for phenotypically and genotypically characterized ciprofloxacin-resistant Salmonella enterica serotype Enteritidis mutants (104-cip and 5408-cip; MIC, >32 microg/ml)...
  17. ncbi Berberis aetnensis C. Presl. extracts: antimicrobial properties and interaction with ciprofloxacin
    Rosario Musumeci
    Department of Microbiological and Gynaecological Sciences, Section of Microbiology, University of Catania, Via Androne 81, 95124 Catania, Italy
    Int J Antimicrob Agents 22:48-53. 2003
    ..In fact, the activity of ciprofloxacin was improved when two chromatographic fractions isolated from leaf extracts were added...
  18. pmc Azithromycin and ciprofloxacin resistance in Salmonella bloodstream infections in Cambodian adults
    Erika R Vlieghe
    Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Antwerp, Belgium
    PLoS Negl Trop Dis 6:e1933. 2012
    ..We describe Salmonella BSI isolates recovered from patients presenting at Sihanouk Hospital Centre of Hope, Phnom Penh, Cambodia (July 2007-December 2010)...
  19. ncbi Curcumin reduces the antimicrobial activity of ciprofloxacin against Salmonella typhimurium and Salmonella typhi
    Sandhya A Marathe
    Department of Microbiology and Cell Biology, Centre for Infectious Disease Research and Biosafety Laboratories, Indian Institute of Science, Bangalore 560012, India
    J Antimicrob Chemother 68:139-52. 2013
    Typhoidal and non-typhoidal infection by Salmonella is a serious threat to human health. Ciprofloxacin is the last drug of choice to clear the infection...
  20. ncbi Comparison of the prevalence and changing resistance to nalidixic acid and ciprofloxacin of Shigella between Europe-America and Asia-Africa from 1998 to 2009
    Bing Gu
    Department of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, Guangzhou Road No 300, Nanjing 210029, China
    Int J Antimicrob Agents 40:9-17. 2012
    ..0. In the area of Asia-Africa, resistance rates to nalidixic acid and ciprofloxacin were 33.6% [95% confidence interval (CI) 21.8-46.6%] and 5.0% (95% CI 2.8-7.8%), respectively, 10.5 and 16...
  21. ncbi The effect of freeze-drying with different cryoprotectants and gamma-irradiation sterilization on the characteristics of ciprofloxacin HCl-loaded poly(D,L-lactide-glycolide) nanoparticles
    S Bozdag
    Laboratory of Pharmaceutical Technology and Biopharmacy, Department of Pharmaceutical Sciences, University of Antwerp, Universiteitsplein 1, 2610 Antwerp, Belgium
    J Pharm Pharmacol 57:699-707. 2005
    ..cryoprotective agents and gamma (gamma)-irradiation sterilization on the physicochemical characteristics of ciprofloxacin HCl-loaded poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles was evaluated...
  22. pmc Mechanism of plasmid-mediated quinolone resistance
    John H Tran
    Infectious Disease Department, Lahey Clinic, Burlington, MA 01805, USA
    Proc Natl Acad Sci U S A 99:5638-42. 2002
    ..Purified Qnr-His(6) protected Escherichia coli DNA gyrase from inhibition by ciprofloxacin. Gyrase protection was proportional to the concentration of Qnr-His(6) and inversely proportional to the ..
  23. ncbi Ciprofloxacin resistance in Campylobacter jejuni evolves rapidly in chickens treated with fluoroquinolones
    Patrick F McDermott
    Division of Animal and Food Microbiology, Center for Veterinary Medicine, US Food and Drug Administration, Laurel, Maryland 20708, USA
    J Infect Dis 185:837-40. 2002
    ..of sarafloxacin and enrofloxacin treatment of Campylobacter jejuni-infected chickens on the development of ciprofloxacin resistance were measured. Fecal samples were collected before and after treatment and were cultured for C...
  24. pmc Swarming of Pseudomonas aeruginosa is a complex adaptation leading to increased production of virulence factors and antibiotic resistance
    Joerg Overhage
    Centre for Microbial Diseases and Immunity Research, University of British Columbia, 2259 Lower Mall, Vancouver, BC, Canada
    J Bacteriol 190:2671-9. 2008
    ..In addition, swarming cells exhibited adaptive antibiotic resistance against polymyxin B, gentamicin, and ciprofloxacin compared to what was seen for their planktonic (swimming) counterparts...
  25. ncbi SOS response promotes horizontal dissemination of antibiotic resistance genes
    John W Beaber
    Department of Microbiology, Tufts University School of Medicine and Howard Hughes Medical Institute, 136 Harrison Avenue, Boston, Massachusetts 02111, USA
    Nature 427:72-4. 2004
    ..SOS is induced by a variety of environmental factors and antibiotics, for example ciprofloxacin, and we show that ciprofloxacin induces SXT transfer as well...
  26. ncbi Immunomodulatory effects of quinolones
    Axel Dalhoff
    Institute for Medical Microbiology and Virology, Universitatsklinikum Schleswig Holstein, Campus Kiel, Germany
    Lancet Infect Dis 3:359-71. 2003
    ....
  27. pmc Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates
    Sonia K Morgan-Linnell
    Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas 77030 3411, USA
    Antimicrob Agents Chemother 53:235-41. 2009
    ..In the accompanying report, we found that ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant E...
  28. pmc Symptomatic treatment (ibuprofen) or antibiotics (ciprofloxacin) for uncomplicated urinary tract infection?--results of a randomized controlled pilot trial
    Jutta Bleidorn
    Institute of General Practice Family Medicine, Hanover Medical School, Carl Neuberg Str 1, 30625 Hannover, Germany
    BMC Med 8:30. 2010
    ..This pilot study was set out 1) to make a rough estimate of the equivalence of ibuprofen and ciprofloxacin for uncomplicated urinary tract infection with regard to symptom resolution, and 2) to demonstrate the ..
  29. ncbi Two distinct mutations in gyrA lead to ciprofloxacin and nalidixic acid resistance in Campylobacter coli and Campylobacter jejuni isolated from chickens and beef cattle
    T W Jesse
    Bacterial Epidemiology and Antimicrobial Resistance Research Unit, U S Department of Agriculture, Agricultural Research Service, Athens, GA 30605 2720, USA
    J Appl Microbiol 100:682-8. 2006
    ..point mutations in the gyrA quinolone resistance determining region (QRDR) of Campylobacter coli (n = 27) and Campylobacter jejuni (n = 26) that confer nalidixic acid (NAL) resistance without conferring resistance to ciprofloxacin (CIP).
  30. pmc Prevalence of mutations within the quinolone resistance-determining region of gyrA, gyrB, parC, and parE and association with antibiotic resistance in quinolone-resistant Salmonella enterica
    Deborah J Eaves
    Antimicrobial Agents Research Group, Division of Immunity and Infection, University of Birmingham, Birmingham B15 2TT, United Kingdom
    Antimicrob Agents Chemother 48:4012-5. 2004
    ..Although it is counterintuitive, isolates with a mutation in both gyrA and parC were more susceptible to ciprofloxacin than were isolates with a mutation in gyrA alone.
  31. ncbi Probing the interaction of human serum albumin with ciprofloxacin in the presence of silver nanoparticles of three sizes: multispectroscopic and ζ potential investigation
    Hediyeh Iranfar
    Department of Biology, Faculty of Sciences, Mashhad Branch, Islamic Azad University, Mashhad, Iran
    J Phys Chem B 116:1951-64. 2012
    The binding of ciprofloxacin to human serum albumin (HSA) in the presence and absence of silver nanoparticles of three sizes was investigated for the first time...
  32. ncbi Effect of topical dexamethasone and ciprofloxacin on bacterial flora of healthy conjunctiva
    S S Ermis
    Department of Ophthalmology, School of Medicine, University of Afyon, Kocatepe, Afyon, Turkey
    Eye (Lond) 18:249-52. 2004
    To investigate the effects of topical dexamethasone and ciprofloxacin, alone and in combination, on the colony counts of conjunctival bacterial flora of healthy subjects.
  33. pmc Effects of ciprofloxacin on the expression and production of exotoxins by Clostridium difficile
    Michael John Aldape
    Department of Veterans Affairs Medical Center, Boise, ID, USA
    J Med Microbiol 62:741-7. 2013
    ..However, the mechanism for this is not clear. We compared the effects of subinhibitory concentrations of ciprofloxacin on Toxin A and B gene expression and protein production in recent (strain 039) and historical (strain 5325) BI/..
  34. ncbi Phenotypic changes in ciprofloxacin-resistant Staphylococcus aureus
    Lili R Mesak
    Department of Microbiology and Immunology, University of British Columbia, Life Sciences Institute, 2350 Health Science Mall, Vancouver, BC V6T1Z3, Canada
    Res Microbiol 160:785-91. 2009
    ..fluoroquinolone moxifloxacin induced expression of SOS response genes (lexA, recA, sosA, and umuC) in a ciprofloxacin-resistant Cip(r)I strain of S. aureus...
  35. ncbi Effects of subinhibitory concentrations of amikacin and ciprofloxacin on the hydrophobicity and adherence to epithelial cells of uropathogenic Escherichia coli strains
    Dorota Wojnicz
    Department of Biology and Medical Parasitology, Medical University of Wroclaw, Mikulicza Radeckiego 9, 50 367 Wroclaw, Poland
    Int J Antimicrob Agents 29:700-4. 2007
    The effect of subinhibitory concentrations of amikacin and ciprofloxacin on the hydrophobicity and adherence to uroepithelial cells of Escherichia coli strains was investigated...
  36. pmc Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections
    Patricia Komp Lindgren
    Department of Cell and Molecular Biology, Microbiology Programme, Biomedical Center, Uppsala University, S 751 24 Uppsala, Sweden
    Antimicrob Agents Chemother 47:3222-32. 2003
    ..This correlation suggests that an increased general mutation rate may play a significant role in the development of high-level resistance to fluoroquinolones by increasing the rate of accumulation of rare new mutations...
  37. pmc Ciprofloxacin-resistant Salmonella Kentucky in travelers
    Francois Xavier Weill
    Emerg Infect Dis 12:1611-2. 2006
  38. ncbi In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood
    Kwan Soo Ko
    Asian Pacific Research Foundation for Infectious Diseases, Seoul 135 710, Korea
    Diagn Microbiol Infect Dis 58:111-5. 2007
    ..in vitro activity of fosfomycin and 7 other comparator agents against 307 Escherichia coli isolates including ciprofloxacin-resistant or extended-spectrum beta-lactamase (ESBL)-producing isolates...
  39. ncbi Antimicrobial resistance trends in blood culture positive Salmonella Typhi isolates from Pondicherry, India, 2005-2009
    G A Menezes
    Department of Microbiology, Institute of National Importance, Jawaharlal Institute of Postgraduate Medical Education and Research JIPMER, Pondicherry, India
    Clin Microbiol Infect 18:239-45. 2012
    ..Recently, there has been an upsurge in the occurrence of bacterial isolates that are resistant to ciprofloxacin, and the emergence of broad spectrum β-lactamases in typhoidal salmonellae constitutes a new challenge for ..
  40. ncbi Platelet-rich plasma protects tenocytes from adverse side effects of dexamethasone and ciprofloxacin
    Nasim Zargar Baboldashti
    Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, UK
    Am J Sports Med 39:1929-35. 2011
    ..The authors assessed the ability of PRP to prevent in vitro adverse effects of 2 drugs commonly linked to tendon rupture and tendinopathy, glucocorticoids and fluoroquinolone antibiotics...
  41. pmc Involvement of the lon protease in the SOS response triggered by ciprofloxacin in Pseudomonas aeruginosa PAO1
    Elena B M Breidenstein
    Centre for Microbial Diseases and Immunity Research, University of British Columbia, Vancouver, British Columbia, Canada
    Antimicrob Agents Chemother 56:2879-87. 2012
    ..of deficiencies in cell division, swarming, twitching, and biofilm formation as well as a phenotype of ciprofloxacin supersusceptibility...
  42. ncbi Trimethoprim and ciprofloxacin resistance and prescribing in urinary tract infection associated with Escherichia coli: a multilevel model
    Akke Vellinga
    Discipline of Bacteriology, NUI Galway, Galway, Ireland
    J Antimicrob Chemother 67:2523-30. 2012
    ..Individual and group level factors associated with the probability of antimicrobial resistance of uropathogenic Escherichia coli were analysed in a multilevel model...
  43. pmc Ciprofloxacin resistance in Campylobacter jejuni isolates: detection of gyrA resistance mutations by mismatch amplification mutation assay PCR and DNA sequence analysis
    G Zirnstein
    National Center for Infectious Diseases, Centers for Disease Control and Prevention, Public Health Service, U S Department of Health and Human Services, Atlanta, Georgia 30333, USA
    J Clin Microbiol 37:3276-80. 1999
    The gyrA quinolone resistance determining region was sequenced from 13 ciprofloxacin-resistant and 20 ciprofloxacin-susceptible Campylobacter jejuni isolates...
  44. pmc Factors related to increasing prevalence of resistance to ciprofloxacin and other antimicrobial drugs in Neisseria gonorrhoeae, United States
    Edward Goldstein
    Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Emerg Infect Dis 18:1290-7. 2012
    Using data from the Gonococcal Isolate Surveillance Project, we studied changes in ciprofloxacin resistance in Neisseria gonorrhoeae isolates in the United States during 2002-2007...
  45. ncbi Diversity of individual dynamic patterns of emergence of resistance to quinolones in Escherichia coli from the fecal flora of healthy volunteers exposed to ciprofloxacin
    Victoire de Lastours
    Univ Paris Diderot, EA 3964 Laboratory, Sorbonne Paris Cité, France
    J Infect Dis 206:1399-406. 2012
    Emergence of quinolone-resistant Escherichia coli (QREC) is an increasing clinical challenge mostly originating in fecal microbiota. The dynamics of the emergence of QREC in feces from individuals exposed to ciprofloxacin is unknown.
  46. ncbi Synergistic effects of baicalein with ciprofloxacin against NorA over-expressed methicillin-resistant Staphylococcus aureus (MRSA) and inhibition of MRSA pyruvate kinase
    Ben C L Chan
    Institute of Chinese Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong
    J Ethnopharmacol 137:767-73. 2011
    ..The aim of the present study was to further investigate antibacterial activities of baicalein in association with various antibiotics against selected Staphylococcus aureus strains with known specific drug resistance mechanisms...
  47. pmc Incidence and mechanism of ciprofloxacin resistance in Campylobacter spp. isolated from commercial poultry flocks in the United Kingdom before, during, and after fluoroquinolone treatment
    Deborah J Griggs
    Antimicrobial Agents Research Group, Division of Immunity and Infection, The Medical School, University of Birmingham, Birmingham B15 2TT, United Kingdom
    Antimicrob Agents Chemother 49:699-707. 2005
    ..Multidrug resistance was significantly (P < 0.01) associated with resistance to ciprofloxacin. Twenty-five percent (73 of 290) of ciprofloxacin-resistant isolates but only 13% (24 of 179) of susceptible ..
  48. ncbi Campylobacter susceptibility to ciprofloxacin and corresponding fluoroquinolone concentrations within the gastrointestinal tracts of chickens
    M B Farnell
    Poultry Production and Product Safety Research Unit, Agricultural Research Service, USDA, Fayetteville, AR 72701, USA
    J Appl Microbiol 99:1043-50. 2005
    ..This study evaluated the relationship between Campylobacter susceptibility and enteric fluoroquinolone concentrations in chickens treated with different doses of enrofloxacin...
  49. pmc Ciprofloxacin safety in paediatrics: a systematic review
    Abiodun Adefurin
    Academic Division of Child Health, University of Nottingham, Derbyshire Children s Hospital, Derby DE22 3DT, UK
    Arch Dis Child 96:874-80. 2011
    To determine the safety of ciprofloxacin in paediatric patients in relation to arthropathy, any other adverse events (AEs) and drug interactions.
  50. pmc Characterization of Abcc4 gene amplification in stepwise-selected mouse J774 macrophages resistant to the topoisomerase II inhibitor ciprofloxacin
    Béatrice Marquez
    Universite Catholique de Louvain, Louvain Drug Research Institute, Pharmacologie Cellulaire et Moléculaire, Brussels, Belgium
    PLoS ONE 6:e28368. 2011
    Exposure of J774 mouse macrophages to stepwise increasing concentrations of ciprofloxacin, an antibiotic inhibiting bacterial topoisomerases, selects for resistant cells that overexpress the efflux transporter Abcc4 (Marquez et al...
  51. pmc Suitable disk antimicrobial susceptibility breakpoints defining Salmonella enterica serovar Typhi isolates with reduced susceptibility to fluoroquinolones
    Christopher M Parry
    The Hospital for Tropical Diseases, Wellcome Trust Major Overseas Programme, Oxford University Clinical Research Unit, 190 Ben Ham Tu, Quan 5, Ho Chi Minh City, Vietnam
    Antimicrob Agents Chemother 54:5201-8. 2010
    ..25 μg/ml) or ciprofloxacin (MIC ≥ 0...
  52. ncbi International spread of an epidemic population of Salmonella enterica serotype Kentucky ST198 resistant to ciprofloxacin
    Simon Le Hello
    Institut Pasteur, unité des bactéries pathogènes entériques, Centre national de référence des Salmonella, World Health Organization WHO Collaborating Centre for Reference and Research on Salmonella, Paris, France
    J Infect Dis 204:675-84. 2011
    ..of multidrug-resistant isolates of Salmonella enterica serotype Kentucky displaying high-level resistance to ciprofloxacin. A total of 489 human cases were identified during the period from 2002 (3 cases) to 2008 (174 cases)...
  53. ncbi Restricting ciprofloxacin-induced resistant variant formation in biofilm of Klebsiella pneumoniae B5055 by complementary bacteriophage treatment
    Vivek Verma
    Department of Microbiology, Basic Medical Sciences BMS Block, Panjab University, Chandigarh, India
    J Antimicrob Chemother 64:1212-8. 2009
    ..of lytic bacteriophage as a therapeutic agent against Klebsiella pneumoniae biofilm, alone or in combination with ciprofloxacin, was studied. The pathogenic potential of the resistant variants formed during the treatment was evaluated.
  54. ncbi A randomized trial comparing four Helicobacter pylori eradication regimens: standard triple therapy, ciprofloxacin based triple therapy, quadruple and sequential therapy
    Keyvan Aminian
    Gastrointestinal and Liver Diseases Research Center GLDRC, Razi Hospital, Tehran, Iran
    Trop Gastroenterol 31:303-7. 2010
    ..Helicobacter pylori infection is found in at least 80% of people in developing countries. This randomized controlled trial was performed to evaluate the efficacy of 4 different H. pylori eradication regimens in Iranian patients...
  55. ncbi In vitro and in vivo reduced fitness and virulence in ciprofloxacin-resistant Acinetobacter baumannii
    Y Smani
    Clinic Unit of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville, University Hospital Virgen del Rocío CSIC University of Seville, Seville, Spain
    Clin Microbiol Infect 18:E1-4. 2012
    ..We aimed to study the virulence and fitness cost of ciprofloxacin-resistance in A. baumannii (CipR) compared with the susceptible parental wild-type strain (CipS)...
  56. pmc Emergence of ciprofloxacin-nonsusceptible Streptococcus pyogenes isolates from healthy children and pediatric patients in Portugal
    Renato Pires
    Centro de Recursos Microbiológicos, Departamento de Ciências da Vida, Faculdade de Ciencias e Tecnologia, Universidade Nova de Lisboa, Campus de Caparica, Caparica, Portugal
    Antimicrob Agents Chemother 54:2677-80. 2010
    We describe 66 ciprofloxacin-nonsusceptible Streptococcus pyogenes isolates recovered from colonized and infected children. The ParC S79A substitution was frequent and associated with the emm6/sequence type 382 (emm6/ST382) lineage...
  57. pmc High-level ciprofloxacin resistance from point mutations in gyrA and parC confined to global hospital-adapted clonal lineage CC17 of Enterococcus faecium
    Helen L Leavis
    Department of Internal Medicine, Division of Infectious Diseases and Internal Medicine, Eijkman Winkler Institute, University Medical Center Utrecht, Heidelberglaan 100, Rm G04 614, 3584CX Utrecht, The Netherlands
    J Clin Microbiol 44:1059-64. 2006
    To substantiate a common genetic background of ciprofloxacin-resistant Enterococcus faecium, 32 ciprofloxacin-resistant (Cip(r)) and 31 ciprofloxacin-susceptible (Cip(s)) isolates from outbreaks, clinical infections, surveillances, and ..
  58. ncbi Preparation of in situ-forming ophthalmic gels of ciprofloxacin hydrochloride for the treatment of bacterial conjunctivitis: in vitro and in vivo studies
    Naseem A Charoo
    Department of Pharmaceutics, Faculty of Pharmacy, Hamdard University, New Delhi 110062, India
    J Pharm Sci 92:407-13. 2003
    Sol-to-gel systems of ciprofloxacin hydrochloride were prepared utilizing the phase transition properties of hydroxy propyl methyl cellulose K 15 M grade (HPMC) and carbopol 934...
  59. ncbi Ciprofloxacin use in neonates: a systematic review of the literature
    Florentia Kaguelidou
    Department of Pediatric Pharmacology and Pharmacogenetics, Hopital Robert Debre, APHP INSERM CIC9202 Université Paris 7, Paris, France
    Pediatr Infect Dis J 30:e29-37. 2011
    b>ciprofloxacin has no marketing authorization for use in neonates worldwide but it is prescribed for the treatment of neonatal life-threatening infections, mainly in developing countries and in Europe...
  60. ncbi Emergence of ciprofloxacin-resistant Neisseria meningitidis in North America
    Henry M Wu
    Office of Workforce and Career Development, and the Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    N Engl J Med 360:886-92. 2009
    We report on three cases of meningococcal disease caused by ciprofloxacin-resistant Neisseria meningitidis, one in North Dakota and two in Minnesota. The cases were caused by the same serogroup B strain...
  61. pmc Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy
    Radha K Shandil
    AstraZeneca India Pvt Ltd, Hebbal, Bellary Road, Bangalore 560024, India
    Antimicrob Agents Chemother 51:576-82. 2007
    ..1 mg/liter (sparfloxacin [SPX]) and 0.5 mg/liter (moxifloxacin [MXF], ciprofloxacin [CIP], and ofloxacin [OFX])...
  62. ncbi Dissemination of ST131 and ST393 community-onset, ciprofloxacin-resistant Escherichia coli clones causing urinary tract infections in Korea
    Mi Young Lee
    Asian Pacific Research Foundation for Infectious Diseases ARFID, Seoul, South Korea
    J Infect 60:146-53. 2010
    b>Ciprofloxacin-resistant Escherichia coli is growing concern in clinical settings. In this study, we investigated the distribution of virulence determinants and phylogenetic groups among community-onset, ciprofloxacin-resistant E...
  63. ncbi Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones
    G Alexandrakis
    Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, Florida, USA
    Ophthalmology 107:1497-502. 2000
    ..To study the distribution, current trends, and patterns of resistance to antimicrobial agents of bacterial keratitis isolates in South Florida...
  64. ncbi Nursing homes as a reservoir of extended-spectrum beta-lactamase (ESBL)-producing ciprofloxacin-resistant Escherichia coli
    Paul J Rooney
    Department of Microbiology, Belfast City Hospital, Belfast BT9 7AD, UK
    J Antimicrob Chemother 64:635-41. 2009
    ..To assess the prevalence and risk factors for faecal carriage of fluoroquinolone-resistant, extended-spectrum beta-lactamase (ESBL)-producing, Escherichia coli (MDR E. coli) among residents in nursing homes in Northern Ireland...
  65. ncbi Expansion and countrywide dissemination of ST11, ST15 and ST147 ciprofloxacin-resistant CTX-M-15-type beta-lactamase-producing Klebsiella pneumoniae epidemic clones in Hungary in 2005--the new 'MRSAs'?
    Ivelina Damjanova
    Department of Phage Typing and Molecular Epidemiology, National Center for Epidemiology, Gyali ut 2 6, 1097 Budapest, Hungary
    J Antimicrob Chemother 62:978-85. 2008
    To investigate the molecular epidemiology of ciprofloxacin-resistant CTX-M-15-producing Klebsiella pneumoniae epidemic clones (ECs) isolated from six nosocomial outbreaks and sporadic cases during 2005 in Hungary.
  66. ncbi Quinolone-resistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii
    J Vila
    Department of Microbiology, Hospital Clinic, School of Medicine, University of Barcelona, Spain
    J Antimicrob Chemother 39:757-62. 1997
    ..baumannii and other bacteria. Nine of ten isolates with MICs of ciprofloxacin of > or = 32 mg/L showed a change of Ser80 to Leu and one showed a change of Glu84 to Lys...
  67. ncbi Effect of albumin conformation on the binding of ciprofloxacin to human serum albumin: a novel approach directly assigning binding site
    Basir Ahmad
    Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh U P, India 202002
    Biomacromolecules 7:1350-6. 2006
    ..8-5.2 M urea concentrations. These states displayed characteristic structure and functions. To elucidate the ciprofloxacin (CFX) binding behavior of HSA, the binding of ciprofloxacin with these conformational states of human serum ..
  68. pmc Ciprofloxacin and trimethoprim cause phage induction and virulence modulation in Staphylococcus aureus
    Christiane Goerke
    Institut fur Medizinische Mikrobiologie und Hygiene, Universitatsklinikum Tubingen, Elfriede Aulhorn Str 6, 72076 Tubingen, Germany
    Antimicrob Agents Chemother 50:171-7. 2006
    ..Here, we analyzed the effects of ciprofloxacin and trimethoprim on phage induction and expression of phage-encoded virulence factors by using isolates from ..
  69. ncbi Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin
    Andrea Endimiani
    Laboratorio di Microbiologia, Ospedale di Circolo and Università dell Insubria, Varese, Italy
    Clin Infect Dis 38:243-51. 2004
    ..as "nonfatal disease" using the McCabe and Jackson classification, were investigated with regard to ciprofloxacin and imipenem response...
  70. ncbi Real-time PCR detection of Pseudomonas aeruginosa in clinical and municipal wastewater and genotyping of the ciprofloxacin-resistant isolates
    Thomas Schwartz
    Forschungszentrum Karlsruhe, Department of Environmental Microbiology Water Technology and Geotechnology Division, Institute of Technical Chemistry, Karlsruhe, Germany
    FEMS Microbiol Ecol 57:158-67. 2006
    ..Limitations of the detection system resulting from inhibition or cross-reaction were identified. Ciprofloxacin-resistant P...
  71. ncbi Ciprofloxacin selects for multidrug resistance in Salmonella enterica serovar Typhimurium mediated by at least two different pathways
    Vito Ricci
    University of Birmingham, UK
    J Antimicrob Chemother 63:909-16. 2009
    ..The aim of this study was to understand the role of ramA in conferring multidrug resistance (MDR) in Salmonella enterica serovar Typhimurium...
  72. pmc Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States
    James A Karlowsky
    Focus Technologies, Inc, 13665 Dulles Technology Drive, Suite 200, Herndon, VA 20171 4603, USA
    Antimicrob Agents Chemother 46:2540-5. 2002
    ..To determine trends in the activities of SXT, ampicillin, ciprofloxacin, and nitrofurantoin among urine isolates of Escherichia coli from female outpatients, susceptibility testing ..
  73. pmc Ciprofloxacin-resistant Salmonella enterica serovar Typhimurium strains are difficult to select in the absence of AcrB and TolC
    Vito Ricci
    Antimicrobial Agents Research Group, Division of Immunity and Infection, University of Birmingham, Birmingham B15 2TT, United Kingdom
    Antimicrob Agents Chemother 50:38-42. 2006
    ..Strains were exposed to ciprofloxacin at 2x the MIC in agar, in the presence and absence of Phe-Arg-beta-naphthylamide, an efflux pump inhibitor...
  74. pmc Antibiotic usage and risk of colonization and infection with antibiotic-resistant bacteria: a hospital population-based study
    Evelina Tacconelli
    Department of Infectious Diseases, Universita Cattolica del Sacro Cuore, Rome, Italy
    Antimicrob Agents Chemother 53:4264-9. 2009
    ..methicillin (meticillin)-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and ciprofloxacin-resistant Pseudomonas aeruginosa (CR-PA)...
  75. ncbi Molecular characterization of ciprofloxacin-resistant Salmonella enterica serovar Typhi and Paratyphi A causing enteric fever in India
    R Gaind
    Department of Microbiology, Safdarjung Hospital and Assoc VMMC, New Delhi, India
    J Antimicrob Chemother 58:1139-44. 2006
    ..To define the genetic characteristics and resistance mechanisms of clinical isolates of Salmonella enterica serovar Typhi (S. Typhi) and S. enterica serovar Paratyphi A (S. Paratyphi A) exhibiting high-level fluoroquinolones resistance...
  76. ncbi Beta-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates
    S Nijssen
    Department of Internal Medicine, Division of Emergency Medicine and Infectious Diseases, F 02 126, University Medical Center Utrecht, P O Box 85000, 3508 GA Utrecht, The Netherlands
    Int J Antimicrob Agents 24:585-91. 2004
    ..5% of all isolates). ESBL-production was confirmed with the ESBL-Etest and disk diffusion test in 1.3% of Escherichia coli isolates, 18.4% of Klebsiella pneumoniae, 12.6% of Klebsiella oxytoca and 5.3% of Proteus mirabilis isolates...
  77. ncbi Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis
    David A Talan
    Department of Emergency Medicine, Olive View UCLA Medical Center, 14445 Olive View Dr, North Annex, Sylmar, CA 91342, USA
    Clin Infect Dis 47:1150-8. 2008
    ..High rates of resistance to trimethoprim-sulfamethoxazole (TMP-SMX) among uropathogenic Escherichia coli are recognized, and concerns exist about emerging fluoroquinolone resistance...
  78. pmc Community-acquired versus nosocomial Klebsiella pneumoniae bacteremia: clinical features, treatment outcomes, and clinical implication of antimicrobial resistance
    Cheol In Kang
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
    J Korean Med Sci 21:816-22. 2006
    ..33%, respectively, were extended-spectrum cephalosporin (ESC)-resistant, and 4% and 21%, respectively, were ciprofloxacin (CIP)-resistant...
  79. ncbi Travel-acquired salmonellosis due to Salmonella Kentucky resistant to ciprofloxacin, ceftriaxone and co-trimoxazole and associated with treatment failure
    Jean Marc Collard
    J Antimicrob Chemother 60:190-2. 2007
  80. ncbi The effects of anti-bacterials on the malaria parasite Plasmodium falciparum
    Christopher Dean Goodman
    Plant Cell Biology Research Centre, School of Botany, University of Melbourne, Parkville, Victoria 3010, Australia
    Mol Biochem Parasitol 152:181-91. 2007
    ..This revealed two distinct classes of drug effect. Ciprofloxacin, rifampicin, and thiostrepton had an immediate effect: slowing parasite growth, retarding organellar ..
  81. ncbi The use of a novel biodegradable preparation capable of the sustained release of bacteriophages and ciprofloxacin, in the complex treatment of multidrug-resistant Staphylococcus aureus-infected local radiation injuries caused by exposure to Sr90
    D Jikia
    Tbilisi State Medical University, Tbilisi, Georgia, USA
    Clin Exp Dermatol 30:23-6. 2005
    ..with PhagoBioDerm (a wound-healing preparation consisting of a biodegradable polymer impregnated with ciprofloxacin and bacteriophages) was initiated. Purulent drainage stopped within 2-7 days...
  82. ncbi Implementation of antibiotic rotation protocol improves antibiotic susceptibility profile in a surgical intensive care unit
    Kyla M Bennett
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Trauma 63:307-11. 2007
    ..We assessed the effect of an antibiotic rotation protocol on the antibiotic susceptibility profiles of three clinically relevant gram-negative microorganisms within our surgical intensive care unit (SICU)...
  83. ncbi Interactions of ciprofloxacin with DPPC and DPPG: fluorescence anisotropy, ATR-FTIR and 31P NMR spectroscopies and conformational analysis
    Hayet Bensikaddour
    Universite Catholique de Louvain, Faculty of Medicine, Unité de Pharmacologie Cellulaire et Moléculaire, UCL 73 70, Avenue E Mounier 73, B 1200 Bruxelles, Belgium
    Biochim Biophys Acta 1778:2535-43. 2008
    ..We previously showed that the ability of a fluoroquinolone antibiotic, ciprofloxacin, to induce disorder and modify the orientation of the acyl chains is related to its propensity to be expelled ..
  84. ncbi Characterisation of fluoroquinolone-resistant clinical isolates of Streptococcus pyogenes in Barcelona, Spain
    A Rivera
    Servei de Microbiologia, Hospital de la Santa Creu i Sant Pau, and Unitat de Microbiologia, Departament de Genetica i Microbiologia, Universitat Autonoma de Barcelona, Barcelona, Spain
    Clin Microbiol Infect 11:759-61. 2005
    ..and clonal relationships were determined for six Streptococcus pyogenes isolates with low- or high-level ciprofloxacin resistance...
  85. ncbi Effects of ciprofloxacin on salt marsh sediment microbial communities
    Ana Lucía Córdova-Kreylos
    Department of Land, Air and Water Resources, University of California, Davis, CA, USA
    ISME J 1:585-95. 2007
    ..The purpose of this study was to measure sorption, and effects of ciprofloxacin on microbial community composition, in sediment samples from three California salt marshes...
  86. ncbi High level of ciprofloxacin resistance and its molecular background among Campylobacter jejuni strains isolated in the United Arab Emirates
    Agnes Sonnevend
    Department of Medical Microbiology, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates
    J Med Microbiol 55:1533-8. 2006
    ..5-4 mg l(-1)), 35 isolates (85.4 %) exhibited resistance to ciprofloxacin (MIC 8-64 mg l(-1))...
  87. pmc Treatment failure in a typhoid patient infected with nalidixic acid resistant S. enterica serovar Typhi with reduced susceptibility to ciprofloxacin: a case report from Cameroon
    Njinkeng J Nkemngu
    St John s Maternity and Hospital, Fiango, Kumba, Cameroon
    BMC Infect Dis 5:49. 2005
    ..Treatment failure with fluoroquinolones has been reported in Asia and Europe. We report a case of ciprofloxacin treatment failure in typhoid fever in Cameroon.
  88. pmc Clonal emergence of extended-spectrum beta-lactamase (CTX-M-2)-producing Salmonella enterica serovar Virchow isolates with reduced susceptibilities to ciprofloxacin among poultry and humans in Belgium and France (2000 to 2003)
    Sophie Bertrand
    National Reference Centre for Salmonella and Shigella, Bacteriology Division, Scientific Institute of Public Health, 14 Wytsman Street, B 1050 Brussels, Belgium
    J Clin Microbiol 44:2897-903. 2006
    ..additional resistance to trimethoprim-sulfamethoxazole and tetracycline as well as a reduced susceptibility to ciprofloxacin (MICs of between 0.5 and 1 mug/ml)...
  89. ncbi The effect of aging on migration, proliferation, and collagen expression of tenocytes in response to ciprofloxacin
    Hsiang Ning Chang
    Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taiwan
    J Orthop Res 30:764-8. 2012
    ..Achilles tendon from two age groups (young: 2 months; and near senescent (old): 24 months) were treated with ciprofloxacin. Tenocyte migration and proliferation were assessed by transwell filter migration assay and MTT (3-[4,5-..
  90. ncbi Effect of generics on price and consumption of ciprofloxacin in primary healthcare: the relationship to increasing resistance
    Ulrich S Jensen
    National Center for Antimicrobials and Infection Control, Statens Serum Institut, Copenhagen, Denmark
    J Antimicrob Chemother 65:1286-91. 2010
    ..In December 2001, generic ciprofloxacin was marketed in Denmark...
  91. ncbi Plasma and ear tissue concentrations of enrofloxacin and its metabolite ciprofloxacin in dogs with chronic end-stage otitis externa after intravenous administration of enrofloxacin
    Lynette K Cole
    Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio 43210, USA
    Vet Dermatol 20:51-9. 2009
    The purpose of this study was to measure the concentrations of enrofloxacin and its metabolite ciprofloxacin following intravenous administration of enrofloxacin in the plasma and ear tissue of dogs with chronic end-stage otitis ..
  92. pmc Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility
    Oren Zimhony
    Division of Infectious Diseases, Kaplan Medical Center Rehovot, Hebrew University and Hadassah, Jerusalem, Israel
    Antimicrob Agents Chemother 50:3179-82. 2006
    ..The second isolate developed resistance to ciprofloxacin and the third isolate to piperacillin-tazobactam (PIP-TZ) following sequential therapy with each agent...
  93. ncbi Treatment of staphylococcal implant infection with rifampicin-ciprofloxacin in stable implants
    D P Konig
    Department of Orthopaedic Surgery, Cologne University, Germany
    Arch Orthop Trauma Surg 121:297-9. 2001
    ..as in patients who for certain reasons are inoperable, antibiotic therapy with a combination of rifampicin-ciprofloxacin may be a reasonable treatment option for curing staphyloccocal infection without removal of the implant...
  94. ncbi Oxidative stress induced by ciprofloxacin in Staphylococcus aureus
    M C Becerra
    Departamento de Farmacia, Facultad de Ciencias Quimicas, Universidad Nacional de Cordoba, Haya de la Torre y Medina Allende, Ciudad Universitaria, 5000 Cordoba, Argentina
    Biochem Biophys Res Commun 297:1003-7. 2002
    Staphylococcus aureus with multiple sensitivity to ciprofloxacin, was investigated to detect alterations in the production of superoxide anion (O(2)(-)), other reactive oxidant species (ROS), and superoxide dismutase (SOD), and to relate ..
  95. ncbi Spontaneous mutation frequency and emergence of ciprofloxacin resistance in Campylobacter jejuni and Campylobacter coli
    Marja Liisa Hänninen
    Department of Food and Environmental Hygiene, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland
    J Antimicrob Chemother 60:1251-7. 2007
    We analysed the contribution of spontaneous mutation frequency to the evolution of ciprofloxacin resistance and the diversity of mutations in the quinolone resistance-determining region (QRDR) of gyrA and in the intergenic region, cmeR-..
  96. ncbi Clonal spread in Eastern Asia of ciprofloxacin-resistant Escherichia coli serogroup O25 strains, and associated virulence factors
    Yujiro Uchida
    Department of Clinical Chemistry and Laboratory Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
    Int J Antimicrob Agents 35:444-50. 2010
    ..coli recently became prevalent at least in East Asia and suggest that this might become a public health problem because the strains may acquire resistance to other antimicrobial agents...
  97. ncbi Activity and postantibiotic effect of marbofloxacin, enrofloxacin, difloxacin and ciprofloxacin against feline Bordetella bronchiseptica isolates
    M Carbone
    Istituto di Microbiologia, Facolta di Medicina e Chirurgia, Policlinico Universitario, Torre Biologica, 2 degrees piano, Universita di Messina, 98125, Messina, Italy
    Vet Microbiol 81:79-84. 2001
    ..inhibitory concentration (MIC) and postantibiotic effect (PAE) of marbofloxacin, enrofloxacin, difloxacin and ciprofloxacin were evaluated in vitro against 43 feline-source Bordetella bronchiseptica strains...
  98. ncbi Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism
    Marika T Granfors
    Department of Clinical Pharmacology, University of Helsinki, FIN 00290 Helsinki, Finland
    Clin Pharmacol Ther 76:598-606. 2004
    ..The fluoroquinolone antibiotic ciprofloxacin is only a moderately potent inhibitor of CYP1A2...
  99. pmc Efficacy of ciprofloxacin-releasing bioabsorbable osteoconductive bone defect filler for treatment of experimental osteomyelitis due to Staphylococcus aureus
    Jyri K Koort
    Orthopaedic Research Unit, Department of Orthopaedic Surgery and Traumatology, University of Turku, FIN 20520 Turku, Finland
    Antimicrob Agents Chemother 49:1502-8. 2005
    ..After removal of the bone cement and surgical debridement at 2 weeks, the defect was filled with a ciprofloxacin-containing (7.6% +/- 0...
  100. ncbi Review of resistance of ocular isolates of Pseudomonas aeruginosa and staphylococci from keratitis to ciprofloxacin, gentamicin and cephalosporins
    Mark D P Willcox
    School of Optometry and Vision Science, University of New South Wales, Sydney NSW 2052, Australia
    Clin Exp Optom 94:161-8. 2011
    ..Antibiotic therapy to treat keratitis caused by these bacteria is either monotherapy with a fluoroquinolone or combination therapy with fortified gentamicin...
  101. pmc In vivo selection of Campylobacter isolates with high levels of fluoroquinolone resistance associated with gyrA mutations and the function of the CmeABC efflux pump
    Naidan Luo
    Food Animal Health Research Program, Ohio Agricultural Research and Development Center, Department of Veterinary Preventive Medicine, The Ohio State University, Wooster, Ohio 44691, USA
    Antimicrob Agents Chemother 47:390-4. 2003
    ..These results reveal that Campylobacter is hypermutable in vivo under the selection pressure of FQ and highlight the need for the prudent use of FQ antibiotics...

Research Grants63

  1. In vitro and in vivo efficacy of liposomal ciprofloxacin formulations against Myc
    Igor Gonda; Fiscal Year: 2013
    ..The overall objective of this project is test the efficacy of two new formulations of ciprofloxacin (Ciprofloxacin for Inhalation, CFI, Lipoquin(R);and Dual Release Ciprofloxacin for Inhalation, DRCFI, ..
  2. Ciprofloxacin enhances DNA repair capacity after radiation combined injury
    JULIANN GONG KIANG; Fiscal Year: 2012
    ..Fluoroquinolones, like ciprofloxacin (CIP), are generally well-tolerated and commonly used for treating infections in the general population...
  3. Optimization of novel pyranopyridine efflux pump inhibitors
    Son Truong Nguyen; Fiscal Year: 2013
    ..When combined with ciprofloxacin, MBX-2319 increased bactericidal activity by >10000 fold, and reduces the MIC values of ciprofloxacin, ..
  4. cGMP manufacturing of PBI-220, a broad spectrum immunoadhesin therapeutic against
    LLOYD M YU; Fiscal Year: 2013
    ..We are developing PBI-220, using the Animal Rule, for passive immunotherapy to complement the use of Ciprofloxacin during treatment of this infection...
  5. An Integrated Diagnostic System for Rapid Antimicrobial Susceptibility Testing
    VINCENT JEN JR GAU; Fiscal Year: 2013
    ..With increasing use, however, SXT resistance increased substantially and quinolones such as ciprofloxacin (CIP) became the antibiotic of choice. Not surprisingly, quinolone-resistant uropathogens are on the rise...
  6. Polysaccharide Ecocomposite Materials: Recyclable Synthesis and Applications
    Chieu D Tran; Fiscal Year: 2012
    ..Methods will also be developed to encapsulate ciprofloxacin, an antibiotic drug, into composite materials during the dissolution process with IL and, subsequently, its ..
  7. Development of a Novel Lead Series Against Category A &B Bacterial Pathogens
    Terry L Bowlin; Fiscal Year: 2013
    ..These compounds are also active against ciprofloxacin-resistant Bacillus anthracis (MIC 0.2-0...
  8. Discovery and Preclinical Development of Drugs for Anthrax, Plague and Tularemia
    Christie G Brouillette; Fiscal Year: 2010
    ..Infections of anthrax, plague, and tularemia are currently treated with existing antibiotics such as ciprofloxacin and doxycycline...
  9. Pathogenicity of Shiga Toxin Producing E.coli
    ALISON DAVIS O'BRIEN; Fiscal Year: 2013
    ..the role of diet in host (mouse) response to STEC;and 4) determine the transmissibility of the phage that carries stX2 in O104:H4 with or without ciprofloxacin (cpx) and the impact of cpx treatment on O104:H4 disease.
  10. Medications and the Risk of Sudden Cardiac Death
    Wayne A Ray; Fiscal Year: 2013
    ..Several medications commonly prescribed with antipsychotics, such as fluoxetine and ciprofloxacin, markedly inhibit antipsychotic metabolism, which may increase antipsychotic effective dose and thus the risk ..
  11. Disinfectant-resistant mycobacteria
    Mary Jackson; Fiscal Year: 2013
    ..under study also displayed unusually high levels of resistance to a number of drugs including rifampicin, ciprofloxacin, clarithromycin, erythromycin, vancomycin, tetracycline and linezolid...
  12. Development of Infection-Resistant Suture Materials
    Matthew Phaneuf; Fiscal Year: 2004
    ..properties by employing textile-dyeing techniques to apply the benzene ring-structured antibiotics Ciprofloxacin (Cipro), Doxycycline and Linezolid...
  13. Maltodextrin based antibiotics
    Niren Murthy; Fiscal Year: 2013
    ..The objective of this proposal is to develop a new strategy for targeting ciprofloxacin into drug-resistant Gram-negative bacteria, composed of conjugating maltohexaose to antibiotics...
  14. Development of Infection-Resistant Suture Materials
    Matthew Phaneuf; Fiscal Year: 2007
    ..In Phase I, Ciprofloxacin (Cipro), Linezolid and Doxycycline were successfully incorporated into nylon, silk and polyester (Dacron) ..
  15. Detecting Carbapenem and Quinolone Resistance in Klebsiella pneumoniae using PCR/
    Robert A Bonomo; Fiscal Year: 2010
    ..The early detection and analysis of carbapenem- and ciprofloxacin- resistant K. pneumoniae will enormously assist clinicians treating patients with serious infections...
  16. Development of a simple and effective therapy against post-exposure anthrax
    Jianfeng Zhang; Fiscal Year: 2012
    ..evaluate its immunogenicity and the protection efficacy as a PEP vaccine in conjunction with a short-course ciprofloxacin prophylaxis against respiratory anthrax in A/J mice...
  17. Electroporation and transcutaneous extraction of drugs
    SATHYANARAYANA MURTHY; Fiscal Year: 2006
    ..In Aim1, we will study the time course of unbound concentration of cephalexin, ciprofloxacin, 8-methoxypsoralen and penciclovir in the dermal ECF by ETE in hairless rat model...
  18. Nanosphere-Antibiotic Corneal Contact Lens Delivery System
    CHARLES LEAHY; Fiscal Year: 2009
    ..advantage of this medicated bandage system over traditional therapy is that a consistent dose of antibiotic (ciprofloxacin) will be delivered over a 7-14 day period while protecting the cornea with a hydrogel bandage lens...
  19. Ciprofloxacin enhances DNA repair capacity after radiation combined injury
    JULIANN KIANG; Fiscal Year: 2009
    ..Fluoroquinolones, like ciprofloxacin (CIP), are generally well-tolerated and commonly used for treating infections in the general population...
  20. Antibiotics and Human Microbial Community Dynamics
    David A Relman; Fiscal Year: 2013
    ..healthy human adults, based on deep sequencing of 16S rRNA genes, shotgun DNA sequencing and metabolomic analysis of weekly fecal samples from 20 healthy subjects collected over 25 weeks (with a course of ciprofloxacin during week 13).
  21. Antibiotic Hypersusceptibility Mutations in Bacteria
    Alexander Mankin; Fiscal Year: 2005
    ..inhibitors (erythromycin, linezolid, tetracycline, and chloramphenicol) and fluoroquinolone antibiotics (ciprofloxacin). The molecular mechanisms underlying the effects of the most interesting of these mutations will be analyzed...
  22. MECHANISMS OF TOPOISOMERASE POISONS
    Hiroshi Hiasa; Fiscal Year: 2002
    ..q., ciprofloxacin)...
  23. Antibiotic Potentiators Targeting SOS Induction
    Timothy Opperman; Fiscal Year: 2009
    ..antibiotics that are currently used to treat bacterial infections, such as ampicillin, amoxacillin, and ciprofloxacin, activate the production of a set of proteins collectively referred to as the SOS response...
  24. SYSTEMIC LYMPH NODE SPECIFIC AGENTS
    MIKHAIL PAPISOV; Fiscal Year: 2003
    ..The specific aims are: (1) develop two prototype lymph node specific preparations (of Ciprofloxacin and Tetracycline); (2) investigate, in a rodent model, the degree of drug accumulation inside and in the near ..
  25. Novel antibacterials targeting the 50S ribosomal subunit
    Joyce Sutcliffe; Fiscal Year: 2003
    ..Zyvox is used to treat serious Gram-positive nosocomial infections. Thus, the 50S presents an opportunity to target medical needs and to find new antimicrobials for both community- and hospital-acquired infections. ..
  26. Infection-Resistant Prosthetic Valve Sewing Cuffs
    DONALD DEMPSEY; Fiscal Year: 2004
    ..in vitro with optimum antimicrobial properties via thermofixation (pad/heat) dyeing of the antibiotic ciprofloxacin (Cipro)...
  27. A Mechanistically Novel Antibiotic for Anthrax
    Edward Turos; Fiscal Year: 2004
    ..microbe could develop or be developed into forms that are highly resistant to current antibiotics (such as ciprofloxacin, penicillin and doxycycline), thus rendering our public health system's ability to control anthrax infections ..
  28. Mechanisms of adverse host responses to antibiotics
    Michael Court; Fiscal Year: 2006
    ..This proposal focuses on the fluoroquinolones, particularly ciprofloxacin, which was the primary antibiotic used for anthrax post-exposure prophylaxis, and is an option for treatment ..
  29. Design of Microparticles for Precision Drug Delivery
    Daniel Pack; Fiscal Year: 2004
    ..In this study, we have chosen four model drugs that span a range of sizes and water solubilities: piroxicam, ciprofloxacin, ganciclovir, and cyclosporin...
  30. Respirable ciprofloxacin aerosol for inhaled anthrax
    Brooks Hybertson; Fiscal Year: 2004
    Pulmonary delivery of solid ciprofloxacin aerosol particles is an attractive possibility for chasing anthrax spores into the thoracic lymph nodes and killing the bacteria when the spores germinate...
  31. Infection Resistant Prostethic Valve Sewing Cuffs
    DONALD DEMPSEY; Fiscal Year: 2001
    ..material in vitro with optimum antimicrobial properties via thermofixation (pad/heat) dyeing of the antibiotic ciprofloxacin (Cipro)...
  32. Target and antibiotic discovery in Bacillus anthracis
    Philip Youngman; Fiscal Year: 2002
    ..of antibiotics it has been made resistant to all commonly used drugs such as penicillin, doxycycline and Ciprofloxacin. If one of these antibiotic resistant strains were used in a future terrorist attack there will be limited or ..
  33. INFECTION-RESISTANT POLYURETHANE MATERIALS
    Michael Szycher; Fiscal Year: 2001
    Infection of polymeric biomaterials is a major problem. In phase I, the antibiotic ciprofloxacin (Cipro) was applied to an ionic polyurethane (cPU) using textile dyeing technology, and the application parameters were optimized...
  34. A novel platform to discover biodefense therapeutics
    JOHN TRAWICK; Fiscal Year: 2003
    ..Although antibiotics such as Ciprofloxacin(r) provided a means for treating the anthrax infections that resulted from these attacks, it is generally ..
  35. WEAR DEBRIS OSTEOLYSIS--NEW STRATEGIES FOR PREVENTION
    REGIS O KEEFE; Fiscal Year: 2001
    ..Since some of these agents, including the phosphodiesterase inhibitor ciprofloxacin and pentoxifylline have possible clinical significance, the potential of these various agents to inhibit bone ..
  36. INFECTION RESISTANT POLYURETHANE MATERIALS
    Michael Szycher; Fiscal Year: 1999
    ..The proposal is to optimize and characterize the uptake of Ciprofloxacin by polycarbonate-based polyurethanes...
  37. Therapeutic Targeting of the Infectious Path of Anthrax
    ANTHONY SCOTTO; Fiscal Year: 2003
    ..and possibly a curative condition can be best achieved by a highly targeted dose of inhalation SLIT-ciprofloxacin, which will also reduce systemic dosage during prolonged therapy...
  38. Ciprofloxacin resistance and compensatory Mutations.
    Julian Adams; Fiscal Year: 2004
    ..Such a scenario will be particularly disastrous during an anthrax epidemic in this country, for which ciprofloxacin will be the primary antibiotic of choice...
  39. Point Source Ozonation to Minimize Antibiotic Resistance
    CLAY THOMPSON; Fiscal Year: 2005
    ..can more effectively and efficiently reduce the concentration of two representative antibiotic residuals (ciprofloxacin and levofloxacin) and representative pathogens (total coliform, fecal coliform, and E...
  40. EFFLUX INHIBITORS FOR MYCOBACTERIUM THERAPIES
    PENELOPE MARKHAM; Fiscal Year: 2001
    ..inhibitors of the NorA efflux pump in Staphylococcus aureus which demonstrated synergistic activity with ciprofloxacin and which dramatically reduced the frequency of emergence of ciprofloxacin-resistant mutants...
  41. Development of Human Monoclonal Antibody for Treatment of Anthrax Exposure
    Wolfgang Scholz; Fiscal Year: 2006
    ..anthracis (Ames) spores in combination with a sub-optimal dose of ciprofloxacin. Furthermore, AVP-21D9 alone is highly effective in a rabbit spore challenge model, where a single ..
  42. Development of furanones for treatment of anthrax
    Martin Blaser; Fiscal Year: 2005
    ..b>Ciprofloxacin or daptomycin will be used as comparitors, and synergies with the furanones explored as well...
  43. Enzymology and Genetic Studies of DNA Polymerases
    Michael Botchan; Fiscal Year: 2005
    ..First, topoisomerases are the favored targets of antibiotics such as ciprofloxacin, and anticancer agents, such as etoposide and adriamyin...
  44. Clinical Approaches to Ileal Pouch Dysfunction
    Bo Shen; Fiscal Year: 2005
    ..The AIMS of study are to 1) investigate visceral hypersensitivity using barostat examination of the pouch; 2) conduct a randomized, placebo-controlled clinical trial evaluating the use of amitriptyline in IPS. ..
  45. Novel Targets for Treatment of Pseudomonas aeruginosa
    Philip Lister; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  46. TRANSGENIC MOUSE MODELS OF PANCREATIC EXOCRINE FUNCTION
    ROBERT DE LISLE; Fiscal Year: 2003
    ..That over expresses Muclin in the pancreatic acinar cell using the rat elastase promoter to direct cell specific expression. ..
  47. PATHOGENEISIS OF CYSTIC FIBROSIS IN THE GI SYSTEM
    ROBERT DE LISLE; Fiscal Year: 2003
    ..Pathology and Muclin expression will be compared in CF mice, and CF mice crossed with gastrin deficient mice (lack gastric acid secretion) to normalize intestinal Ph. ..
  48. Plasmid-Mediated Quinolone Resistance
    George Jacoby; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  49. Resistant E.coli in Humans and Poultry
    James Johnson; Fiscal Year: 2005
    ..Does the research address a current and compelling problem of antimicrobial resistance that is of high public health importance and for which research is needed? [yes]. ..
  50. Uptake of Fluoroquinolones and Tetracyclines by Gingiva
    John Walters; Fiscal Year: 2003
    ..Strategies that optimize the uptake and distribution of antimicrobial agents should enhance the elimination of invasive pathogens from the periodontium and other types of mucosa. ..
  51. Ophthalmic Antibiotic Resistance Study
    Kirk Wilhelmus; Fiscal Year: 2003
    ..abstract_text> ..
  52. Bactericidal agents for slow-growing bacteria
    PENELOPE MARKHAM; Fiscal Year: 2003
    ..PTE compounds could provide a unique opportunity for eradication of infections associated with slow bacterial growth. ..
  53. Alternative endpoints for plague challenge models
    Richard Frothingham; Fiscal Year: 2005
    ..We will use the data generated to refine our hypotheses and to pursue further funding to complete Aim 3. ..
  54. Duke University Center for Translational Research
    Richard Frothingham; Fiscal Year: 2006
    ....
  55. Susceptibility Testing, Treatment Choices, and Outcomes of MDR-GNB Infections
    Lisa Saiman; Fiscal Year: 2009
    ..Carefully conducted observational studies and clinically relevant in vitro antimicrobial susceptibility testing, hold the greatest promise to improve the treatment of patients infected with mutidrug-resistant organisms. ..
  56. Aggressive Periodontitis and Formylpeptide Receptor SNPs
    John Walters; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  57. Saccharide-Based Effectors of Cationic Antimicrobial Peptides
    Robert Kerns; Fiscal Year: 2007
    ..We are also investigating if certain types of therapeutic agents inhibit antibacterial activity of the antimicrobial peptides. [unreadable] [unreadable] [unreadable]..
  58. A Nanofibrous Biocomposite Small-Diameter Graft
    Matthew Phaneuf; Fiscal Year: 2006
    ..Potentially, the annual market value for an "off-the-shelf" synthetic arterial bypass graft could exceed $1.5 billion. ..
  59. H2O2-PRODUCING LACTOBACILLI AND POSTMENOPAUSAL UTI
    Kalpana Gupta; Fiscal Year: 2005
    ....
  60. Infection, Inflammation and Preeclampsia
    Catherine Haggerty; Fiscal Year: 2009
    ..Finally, cytokine and CRP testing may prove to be effective tools for identifying women at risk for developing preeclampsia. ..
  61. Discovery of B. pseudomallei Therapeutics for Biodefense
    Donald Moir; Fiscal Year: 2008
    ..pseudomallei targets. In Phase III, a potent, safe, orally active B. pseudomallei inhibitor will be advanced into IND enabling toxicology and safety pharmacology studies and file an IND. [unreadable] [unreadable] [unreadable]..
  62. Mucin-degrading microflora for prophylactic antibiotics
    ROBERT CARMAN; Fiscal Year: 2008
    ..difficile, and reduces the incidence of C. difficile- induced antibiotic-associated diarrhea. [unreadable] [unreadable] [unreadable]..